Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer: Cambridge, UK Tuesday, February 4, 2025, 09:00 Hrs [IST] Astr ...

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.

Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy. It is also approved for ...

AIM ImmunoTech (AIM) announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM’s ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The approval was based on data from the ADRIATIC phase III study for LS-SCLC patients. Imfinzi was approved by the FDA for a similar use in LS-SCLC in November last year. PFE, LLY, NVO and AZN ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...